Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game

Whenever I think about the thesis for Pfizer Inc. ( PFE ), I can't help but ruminate over why the market has not shown much conviction despite PFE trading at valuations that are still undisputablyJR Research is an opportunistic investor. I was recognized by TipRanks as a Top Analyst, and also by Seeking Alpha as a "Top Analyst To Follow" for Technology, Software, and Internet, as well as for Growth and GARP. I identify attractive risk/reward opportunities supported by robust price action to potentially gene ...